Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

5(71.4%)

Phase 2

1(14.3%)

Phase 3

1(14.3%)

7Total

Phase 1(5)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07138014Phase 2Not Yet Recruiting

FHND1002 for ALS Treatment: Phase 2

Role: lead

NCT06782958Phase 1Enrolling By Invitation

Safety, Tolerability, and Pharmacokinetics of FHND1002 Granules in Healthy Adults

Role: lead

NCT06762743Phase 1Enrolling By Invitation

Bioequivalence Study of Two Brivaracetam Oral Solutions in Healthy Adults Under Fasting and High-Fat Meal Conditions

Role: lead

NCT06759857Phase 3Enrolling By Invitation

FHND9041 Versus Afatinib for Non-small Cell Lung Cancer

Role: lead

NCT06521034Phase 1Completed

First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer

Role: collaborator

NCT05271682Phase 1Unknown

A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple Myeloma

Role: lead

NCT05818917Phase 1Unknown

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of FHND5071 as a Single Agent in Adult Patients With Advanced Solid Tumors

Role: lead

All 7 trials loaded